Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) generates news primarily around the development of its prescription transdermal pharmaceutical products and its proprietary AVERSA abuse-deterrent transdermal technology. The company’s updates frequently focus on its lead product under development, an abuse-deterrent fentanyl transdermal system known as AVERSA FENTANYL, and on efforts to address the risks of abuse, diversion, misuse, and accidental exposure associated with transdermal opioid therapies.
News about Nutriband often covers clinical and regulatory milestones, such as meetings with the U.S. Food and Drug Administration (FDA) to discuss Chemistry, Manufacturing, and Controls plans, regulatory pathways under the 505(b)(2) NDA framework, and feedback on studies designed to characterize abuse-deterrent properties. Press releases also highlight patent developments, including Notices of Allowance, newly issued patents for abuse and misuse deterrent transdermal systems, and provisional patent applications intended to enhance AVERSA’s aversive formulations and coating methods.
Investors following NTRB and NTRBW can also expect corporate and strategic news, including stock dividends of Series A Convertible Preferred Stock, exercises of stock options and warrants, and transactions such as the agreement to sell a majority interest in the Pocono Pharmaceutical subsidiary to EarthVision Bio. Nutriband’s communications may additionally cover index inclusions, shareholder letters discussing milestones and outlook, and participation in investor conferences where management presents operational highlights and the strategic direction of the AVERSA platform.
This news page aggregates these developments into a single feed, allowing readers to review Nutriband’s announcements on product development, intellectual property, regulatory interactions, capital structure, and strategic initiatives related to its abuse-deterrent transdermal technology and lead fentanyl patch program.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced the receipt of $2,062,500 from the exercise of 275,000 warrants at $7.50 each, linked to its earlier public offering on October 1, 2021. This adds to the $6,600,000 garnered from the sale of 1,056,000 shares, bringing the total gross proceeds to approximately $8,662,500 as of October 21, 2021. Nutriband focuses on developing transdermal pharmaceutical products, particularly an abuse deterrent fentanyl patch utilizing its AVERSA technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has entered an exclusive manufacturing agreement with Diomics for its Diocheck™ technology, aimed at monitoring COVID-19 antibody levels. This transdermal patch provides results within 24 to 36 hours and remains effective for up to 14 days. The device is intended for assessing the effectiveness of COVID-19 vaccines over time, helping identify when boosters may be needed. The partnership showcases Nutriband's capabilities in innovative patch technologies, bolstering its position in the pharmaceutical market.
Nutriband Inc. (NASDAQ: NTRB, NTRBW) announced an underwritten public offering of 1,056,000 units priced at $6.25 per unit, generating gross proceeds of $6.6 million. Each unit consists of one share of common stock and one warrant. The warrants are exercisable at $7.50 and expire in five years. The offering includes a 45-day option for underwriters to purchase additional shares and warrants. This uplisting to the Nasdaq Capital Market aims to enhance visibility and support the company's strategic growth initiatives in developing transdermal pharmaceutical products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that it received a Notice of Allowance from the USPTO for patent application 16/707,547, focusing on its AVERSA® technology. This technology targets the prevention of opioid abuse, particularly for fentanyl patches. The announcement follows the company's initial NASDAQ listing and a $6.6 million underwritten offering on October 1, 2021. The proceeds will primarily fund the clinical development of AVERSA.
Nutriband Inc. (NASDAQ: NTRB, NTRBW) announced its common stock and warrants began trading on the Nasdaq Capital Market on October 1, 2021. The company also priced an underwritten public offering of 1,056,000 units at $6.25 per unit, aiming for total gross proceeds of $6.6 million. Each unit comprises one share of common stock and one warrant, entitling the holder to purchase additional stock at an exercise price of $7.50. A 45-day option allows underwriters to purchase up to 158,400 additional shares to cover over-allotments. CEO Gareth Sheridan noted that this uplisting is a significant milestone for corporate visibility.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced the pricing of an underwritten public offering of 1,056,000 units at $6.25 per unit, totaling gross proceeds of $6.6 million. This offering will fund the development of its abuse deterrent fentanyl patch incorporating AVERSA technology. Additionally, Nutriband's securities will commence trading on the Nasdaq Capital Market as of October 1, 2021. The company has granted underwriters a 45-day option to purchase additional shares and warrants to cover over-allotments. CEO Gareth Sheridan emphasized the uplisting's potential to enhance corporate visibility.